The combined treatment with L1CAM antibodies and chemotherapeutic drugs in pancreatic and ovarian carcinoma model systems in vivo reduced tumor growth more efficiently than treatment with the cytostatic drug alone [75], indicating the value of L1CAM as a target for chemosensitizer in anticancer therapy for aggressive EC. The gene discussed is L1CAM; the disease is neoplasm.